(Q34389383)

1 August 2017

title

Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy (English)

1 reference

1 August 2017

1 reference

1 reference

neoadjuvant chemotherapy

1 reference

2

Hiroaki Itamochi

1 reference

1 August 2017

Seiya Sato

1

1 reference

1 August 2017

publication date

1 November 2014

1 reference

Therapeutic advances in medical oncology

1 August 2017

published in

1 reference

1 August 2017

volume

6

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

293-304

1 reference

Role of neoadjuvant chemotherapy in the management of advanced ovarian yolk sac tumor

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

A phase 3 trial of bevacizumab in ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

6 July 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Estimates of cancer incidence and mortality in Europe in 2008.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Clinicopathological characteristics of mucinous adenocarcinoma of the ovary

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

What is the role of neoadjuvant chemotherapy in the management of ovarian cancer?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Future options for first-line therapy of advanced ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834014544891

Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206650

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma

27 October 2018

1 reference

12 December 2020

Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer

1 reference

12 December 2020

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

1 reference

12 December 2020

Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery

1 reference

12 December 2020

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

12 December 2020

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

12 December 2020

Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking

1 reference

12 December 2020

Role of Neoadjuvant Chemotherapy in the Management of Stage IIIC–IV Ovarian Cancer: Survey Results from the Members of the European Society of Gynecological Oncology

1 reference

12 December 2020

Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer

1 reference

12 December 2020

A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma

1 reference

12 December 2020

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

1 reference

12 December 2020

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

12 December 2020

Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?

1 reference

12 December 2020

Early versus delayed treatment of relapsed ovarian cancer

1 reference

12 December 2020

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

1 reference

12 December 2020

Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer

1 reference

12 December 2020

Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer

1 reference

12 December 2020

Bevacizumab and ovarian cancer

1 reference

12 December 2020

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

12 December 2020

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

1 reference

12 December 2020

Neoadjuvant chemotherapy for advanced ovarian cancer

1 reference

12 December 2020

Identifiers

DOI

10.1177/1758834014544891

1 reference

1 August 2017

1 reference

1 August 2017

1 reference